Catalyzes the reductive methylation of 2'-deoxyuridine 5'-monophosphate (dUMP) to thymidine 5'-monophosphate (dTMP), using the cosubstrate, 5,10- methylenetetrahydrofolate (CH2H4folate) as a 1-carbon donor and reductant (Probable). Contributes to the mitochondrial and nuclear de novo thymidylate biosynthesis pathway (By similarity)
Homodimer (PubMed:9894005). Part of the de novo thymidylate synthesis complex composed at least by SHMT1, DHFR and TYMS. Interacts with SHMT1; this interaction is DNA-dependent and mediates TYMS co-localization with LMNB1 (By similarity)
No mutation information available.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to TYMS, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 38
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT02296671 | Esophagogastric Cancer | Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers | PHASE2 | WITHDRAWN |
| NCT02919462 | Carcinoma, Non-Small-Cell Lung, Secondary, Advanced Stage IIIB, High Thymidylate Synthase Expression | Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression | PHASE2 | TERMINATED |
| NCT05873686 | Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | PHASE1 | RECRUITING |
| NCT03741829 | Small Cell Lung Cancer | TS Overexpression in SCLC: Mechanism and Therapeutic Targeting | N/A | COMPLETED |
| NCT06976892 | High Grade Serous Ovarian Cancer | Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer | PHASE1 | RECRUITING |
| NCT00001341 | Neoplasm | A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease | PHASE1 | COMPLETED |
| NCT00098787 | Colorectal Cancer | Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer | PHASE2 | COMPLETED |
| NCT01401192 | Non-small Cell Lung Cancer | Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression | PHASE2 | UNKNOWN |
| NCT00515216 | Stomach Neoplasms, Esophageal Neoplasms | Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors | PHASE2 | COMPLETED |
| NCT00004187 | Colorectal Cancer | Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer | PHASE1, PHASE2 | COMPLETED |